140,971 Guardant Health, Inc. $GH Shares Acquired by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC increased its position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 55.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 395,281 shares of the company’s stock after purchasing an additional 140,971 shares during the quarter. Stephens Investment Management Group LLC’s holdings in Guardant Health were worth $70,502,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of GH. Ninepoint Partners LP purchased a new position in Guardant Health in the second quarter valued at about $2,853,000. Orbimed Advisors LLC purchased a new stake in Guardant Health during the 1st quarter worth approximately $40,199,000. GSA Capital Partners LLP acquired a new position in shares of Guardant Health in the 2nd quarter valued at approximately $1,772,000. Eagle Health Investments LP acquired a new position in shares of Guardant Health in the 2nd quarter valued at approximately $45,112,000. Finally, SWS Partners acquired a new position in shares of Guardant Health in the 2nd quarter valued at approximately $11,190,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CTO Darya Chudova sold 7,738 shares of Guardant Health stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total transaction of $1,377,364.00. Following the sale, the chief technology officer directly owned 70,635 shares in the company, valued at approximately $12,573,030. This trade represents a 9.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve Krognes sold 6,674 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total value of $1,172,888.76. Following the transaction, the director directly owned 7,906 shares in the company, valued at $1,389,400.44. This represents a 45.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 53,224 shares of company stock worth $9,116,546. Company insiders own 5.60% of the company’s stock.

Analyst Upgrades and Downgrades

GH has been the subject of a number of recent analyst reports. The Goldman Sachs Group reissued a “buy” rating and set a $210.00 price target on shares of Guardant Health in a research report on Friday, July 31st. Stephens raised their target price on Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a report on Wednesday. Sanford C. Bernstein reissued an “outperform” rating and set a $210.00 price target on shares of Guardant Health in a research note on Thursday, September 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and an average price target of $190.88.

Check Out Our Latest Stock Analysis on Guardant Health

Guardant Health Stock Up 1.3%

GH stock opened at $145.14 on Thursday. Guardant Health, Inc. has a 12 month low of $74.55 and a 12 month high of $191.05. The firm has a market cap of $19.64 billion, a P/E ratio of -39.44 and a beta of 1.67. The company’s 50-day moving average price is $167.58 and its two-hundred day moving average price is $133.48.

Guardant Health (NASDAQ:GH – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.46. The business had revenue of $360.98 million for the quarter, compared to the consensus estimate of $350.72 million. The company’s revenue was up 36.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.74) earnings per share. Equities analysts predict that Guardant Health, Inc. will post -3.28 EPS for the current year.

Guardant Health Profile

(Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

See Also

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.